SCHEMBL14474741

SCHEMBL14474741

COc1cc(-c2cc(F)ccc2F)cc2c(N3CC(OC)C3)nc(-c3cccnc3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ GAA P10253 3/20 0.41
▸ GBA1 P04062 3/20 0.39
▸ LMNA P02545 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ TTK P33981 1/20 0.38
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ BACE1 P56817 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ APLNR P35414 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474744 0.93 MAPT (0.41) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL14475266 0.92 MAPT (0.41) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184702 0.91 MAPT (0.44) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16183254 0.90 KDM4E (0.41) MAPTGBA1LMNAKDM4ENPSR1
SCHEMBL16184060 0.90 MAPT (0.43) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184780 0.89 MAPT (0.45) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184770 0.89 MAPT (0.47) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184718 0.89 MAPT (0.43) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184801 0.89 MAPT (0.44) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL14474745 0.88 MAPT (0.41) MAPTALDH1A1GAAGBA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885ALDH1A1 1687/4885GAA 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback